Panel: (Inter)nationalising the antibiotic pipeline: public options for antibiotic R&D

19 November 2019

Portrait of Dr Claas Kirchhelle

with Dr Claas Kirchhelle
Research Associate, Wellcome Unit for the History of Medicine

I am a Lecturer of the History of Medicine at University College Dublin, Fellow of the Oxford Martin School, and Junior Research Fellow at Wolfson College (Oxford). My research fuses the History of Science, Medicine, and Environmental History with ap...

Portrait of Dr Javier Lezaun

with Dr Javier Lezaun
James Martin Lecturer in Science and Technology Governance

Javier Lezaun is a James Martin Lecturer in Science and Technology Governance; Lead Researcher at the Institute for Science, Innovation and Society in the School of Anthropology and Museum Ethnography and Fellow of Kellogg College.Dr Lezaun's researc...

Over the past three decades, the rapid rise of antimicrobial resistance and the lack of new antibiotics have created a perfect storm for global health and food systems. Antibiotic effectiveness is an endangered global common resource in urgent need of new solutions to protect existing drugs and to develop novel compounds.

This event brings together experts from the medical, natural, and social sciences to discuss both the status quo and new approaches to global drug development and stewardship. In addition to the current focus on using public money to reinvigorate private drug development, panellists will discuss alternatives such as a public buyout of existing patents and a long-term (inter)nationalisation of antibiotic development as well as solutions for the dilemma of curbing AMR and enhancing global access to effective antimicrobials.

Dr Andrew Singer (microbiologist, UK Centre for Ecology & Hydrology), Dr Claas Kirchhelle (historian, Oxford Martin School), Dr Adam Roberts (microbiologist, Liverpool School of Tropical Medicine) introduce their new publication on public options for antibiotic development in Lancet Infectious Diseases.

An expert panel then discuss the economic, social, and microbiological dimensions of drug development, stewardship, and infection control in the 20th and 21st centuries;

Moderator: Prof Jamie Lorimer (Geography, University of Oxford)

Prof Ellen Silbergeld (environmental and public health, Johns Hopkins University),

Dr Koen Pouwels (modeller and economist, University Oxford),

Prof Viviane Quirke (historian, Oxford Brookes University),

Prof Javier Lezaun (social scientist, Institute for Science, Innovation, and Society, Oxford)